期刊文献+

72例朗格汉斯细胞组织细胞增生症患儿临床分析

Clinical analysis of 72 children with Langerhans cell histiocytosis
暂未订购
导出
摘要 目的分析儿童朗格汉斯细胞组织细胞增生症(Langerhans cell histiocytosis,LCH)的临床特点、疗效和预后。方法对72例初发LCH患儿进行回顾性分析。结果72例患儿中位年龄为5岁(范围:0~14岁),颅骨受累最常见(56例,78%);BRAF-V600E突变与临床特征、疗效及预后无关(P>0.05);5年总生存率91.6%±4.2%,5年无事件生存(event-free survival,EFS)率67.5%±5.8%。危险器官受累组6周化疗有效率和5年EFS率低于无危险器官受累组(P<0.05);多系统受累组、血小板≥450×10^(9)/L组5年总生存率分别低于单系统受累组和血小板<450×10^(9)/L组(P<0.05)。其中危险器官受累是影响5年EFS的独立危险因素(P<0.05)。结论颅骨是儿童LCH最常累及部位。BRAF-V600E突变与其临床特征、疗效及预后无关。血小板增高、危险器官受累、多系统受累与预后不良相关,危险器官受累为5年EFS的独立危险因素。 Objective To study the clinical characteristics,efficacy,and prognosis of pediatric Langerhans cell histiocytosis(LCH).Methods A retrospective analysis was conducted on 72 children with newly diagnosed LCH.Results The median age of the 72 children was 5 years(range:0-14 years),with skull involvement being the most common(56 cases,77.8%).The BRAF-V600E mutation was not associated with clinical characteristics,efficacy,or prognosis(P>0.05).The 5-year overall survival rate was 91.6%±4.2%,and the 5-year event-free survival(EFS)rate was 67.5%±5.8%.The 6-week chemotherapy response rate and 5-year EFS rate were lower in the risk organ involvement group compared to the no risk organ involvement group(P<0.05).The five-year overall survival rates for the group with multi-system involvement and the group with platelet count≥450×109/L were respectively lower than those for the single-system involvement group and the group with platelet count<450×109/L(P<0.05).Risk organ involvement is an independent risk factor for 5-year EFS(P<0.05).Conclusions Skull is the most commonly affected site in pediatric LCH.The BRAF-V600E mutation is not related to clinical characteristics,efficacy,or prognosis.Elevated platelet count,risk organ involvement,and multisystem involvement are associated with poor prognosis,with risk organ involvement being an independent risk factor for 5-year EFS.
作者 蒋文轩 叶芳华 肖逸心 邓文军 俞燕 杨良春 JIANG Wen-Xuan;YE Fang-Hua;XIAO Yi-Xin;DENG Wen-Jun;YU Yan;YANG Liang-Chun(Department of Pediatric Hematology,Xiangya Hospital of Central South University,Changsha 410008,China)
出处 《中国当代儿科杂志》 北大核心 2025年第5期555-562,共8页 Chinese Journal of Contemporary Pediatrics
基金 湖南省自然科学基金项目(2024JJ5598) 长沙市科技计划项目(kq2403024)。
关键词 朗格汉斯细胞组织细胞增生症 临床特征 BRAF基因 预后 儿童 Langerhans cell histiocytosis Clinical characteristics BRAF gene Prognosis Child
  • 相关文献

参考文献6

二级参考文献36

  • 1Alexander K.C.Leung,Joseph M.Lam,Kin Fon Leong.Childhood Langerhans cell histiocytosis:a disease with many faces[J].World Journal of Pediatrics,2019,15(6):536-545. 被引量:14
  • 2Alexander K.C.Leung,Alexander A.C.Leung.Evaluation and management of the child with hypothyroidism[J].World Journal of Pediatrics,2019,15(2):124-134. 被引量:11
  • 3王宏胜,李军,马伴吟,高怡瑾,陆凤娟,钱晓文.改良DAL-HX83/90方案治疗儿童郎格罕细胞组织细胞增生症24例疗效观察[J].中国小儿血液与肿瘤杂志,2007,12(2):60-63. 被引量:12
  • 4Histiocyte Society. Langerhans cell histiocytosis evaluation and treatment guideline. April,2009. Availabele from : http ://www. heamatologie-amc, nl/odijk/bijlagen.
  • 5Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs, 2011,13 : 75 -86.
  • 6Gadner I-I, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histioeytosis. J Pediatr, 2001, 138:728-734.
  • 7treatment ot multisystem Langerhans cell histiocytosis : important prognostic indicator. Med Pediatr Oncol, 2002,39:581- 585.
  • 8Bernard F, Thomas C, Bertrand Y,et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside corobined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer, 2005,41:2682-2689.
  • 9Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced- intensity conditioning. Bone Marrow Transplant, 2005,36: 215- 225.
  • 10Egeler RM, de Kraker J, Vo6te PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol, 1993,21: 265-270.

共引文献110

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部